"3-4 years, at least, of mortaility benefit and reduction in major vascular events like heart attacks and strokes. That would be complementary to all existing small molecule approaches...."
Basically hs is looking to combine with another big Pharma with a treatment that reduces hospitalizations in a commercial partnership. 60% reduction in mortality! Nothing else is close. The market has this one wrong again. Feels like the time the stock collasped pre-ODAC meeting on FDA initial response. Massive buy-in opportunity.
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-309
-
- There are more pages in this discussion • 714 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |